Plant Name: Aconitum heterophylloides
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| RECQL; TDP1; P4HB; PIK3CA; PIK3CB; TERT; PKM; HPGD; PGD; ALOX12; AKR1B1; GFER; NQO2; ALDH1A1; POLB; | |
| GAA; | |
| BCL2; | |
| SYK; MET; MAPK14; DYRK1A; | |
| CA2; CA1; CA12; CA9; CA13; CA3; CA5B; CA4; CA5A; CA7; CA14; CA6; | |
| ESR1; | |
| KDM4E; | |
| PTGS1; MAOA; PTGS2; | |
| BACE1; | |
| MMP2; MMP14; | |
| HIF1A; TP53; | |
| FUT7; | |
| DNMT1; | |
| ABCB1; | |
| SLC6A2; | |
| HTT; NPC1; LMNA; MAPT; GMNN; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP14 | Matrix metalloproteinase 14 | P50281 | CHEMBL3869 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 9.926E-11 | 1.965E-07 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, DNMT1, ESR1, MMP14, MMP2, NQO2, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.017E-09 | 1.231E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.936E-08 | 1.317E-05 | CA2, CA7, HIF1A, HTT, MAPK14, NPC1, PIK3CB, PTGS2, SYK |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.266E-08 | 1.452E-05 | BCL2, HIF1A, LMNA, P4HB, PTGS2, TERT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.313E-08 | 2.061E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.725E-08 | 4.604E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 6.143E-07 | 2.229E-04 | AKR1B1, APP, CYP1A2, CYP2C19, CYP2C9, CYP3A4, ESR1, NPC1 |
| BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 8.046E-07 | 2.717E-04 | HIF1A, MAPK14, MMP14, MMP2, PIK3CA, PIK3CB, PTGS2, SYK |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.051E-06 | 3.366E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, NQO2, PTGS1 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.128E-06 | 3.560E-04 | BCL2, CA2, CA7, HIF1A, HTT, MAPK14, NPC1, PIK3CB, PTGS2, SYK |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.071E-06 | 5.933E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, PTGS1, PTGS2 |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 2.019E-06 | 5.933E-04 | AKR1B1, APP, BACE1, BCL2, CA13, CA4, CA5A, CA5B, CYP1A2, CYP2C19, CYP2C9, CYP3A4, DNMT1, DYRK1A, ESR1, FUT7, GAA, GFER, GMNN, HIF1A, HTT, KDM4E, LMNA, MAOA, MAPK14, MAPT, MMP14, MMP2, NPC1, P4HB, PGD, PIK3CB, PKM, POLB, PTGS1, PTGS2, RECQL, SYK, TDP1, TERT, TP53 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.881E-06 | 7.842E-04 | ABCB1, CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.881E-06 | 7.842E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 3.168E-06 | 8.115E-04 | AKR1B1, ALDH1A1, ALOX12, APP, BCL2, CYP3A4, HIF1A, MAOA, NPC1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.697E-29 | 1.240E-24 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 4.185E-06 | 1.024E-03 | ALOX12, PTGS1, PTGS2, SYK |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.260E-06 | 1.259E-03 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0051213; dioxygenase activity | 6.789E-06 | 1.590E-03 | ALOX12, KDM4E, P4HB, PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 8.556E-06 | 1.941E-03 | PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.276E-06 | 2.061E-03 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.328E-05 | 2.891E-03 | ALOX12, HPGD, PTGS2 |
| CC | GO:0044464; cell part | GO:0044444; cytoplasmic part | 1.422E-05 | 3.007E-03 | AKR1B1, ALDH1A1, ALOX12, APP, BACE1, BCL2, CA1, CA13, CA2, CA3, CA4, CA5A, CA5B, CA7, CYP1A2, CYP2C19, CYP2C9, CYP3A4, ESR1, FUT7, GAA, GFER, GMNN, HIF1A, HPGD, HTT, LMNA, MAOA, MAPK14, MAPT, MMP14, MMP2, NPC1, NQO2, P4HB, PGD, PIK3CA, PIK3CB, PKM, PTGS1, PTGS2, SYK, TERT, TP53 |
| BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 1.859E-05 | 3.713E-03 | BCL2, CA2, CA9, ESR1, HIF1A, MET, MMP14 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.562E-05 | 4.768E-03 | CA2, CA7 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 2.657E-05 | 4.862E-03 | APP, BCL2, GAA, HIF1A, HTT, MAPT, NPC1, PTGS2, TP53 |
| BP | GO:0065007; biological regulation | GO:0044093; positive regulation of molecular function | 3.024E-05 | 5.442E-03 | ABCB1, ALDH1A1, APP, BCL2, ESR1, GMNN, HIF1A, HTT, MAPK14, MAPT, MET, MMP14, PIK3CA, PIK3CB, SYK, TERT |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.120E-05 | 5.569E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 3.605E-05 | 6.140E-03 | HIF1A, TERT, TP53 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 3.605E-05 | 6.140E-03 | HPGD, MMP2, TERT |
| BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 4.160E-05 | 6.862E-03 | AKR1B1, ALOX12, CYP3A4, PGD, PKM, PTGS1, PTGS2, SYK |
| BP | GO:0009987; cellular process | GO:0010821; regulation of mitochondrion organization | 5.294E-05 | 8.233E-03 | BCL2, HIF1A, HTT, LMNA, MAPT, TP53 |
| BP | GO:0008152; metabolic process | GO:0010507; negative regulation of autophagy | 5.714E-05 | 8.824E-03 | BCL2, MET, NPC1, PIK3CA |
| BP | GO:0008152; metabolic process | GO:0006693; prostaglandin metabolic process | 6.036E-05 | 9.065E-03 | HPGD, PTGS1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:1901701; cellular response to oxygen-containing compound | 6.405E-05 | 9.423E-03 | AKR1B1, APP, DNMT1, ESR1, MAPK14, MMP2, PIK3CA, PKM, PTGS2, TP53 |
| BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 6.722E-05 | 9.694E-03 | HIF1A, MET, P4HB, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.481E-21 | 2.701E-17 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.008E-20 | 1.775E-16 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.082E-28 | 7.979E-26 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.999E-08 | 1.867E-06 | CYP2C9; APP; MAOA; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.568E-08 | 1.867E-06 | PKM; PIK3CA; PIK3CB; TP53; MET; HIF1A |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.059E-07 | 4.156E-06 | PIK3CA; MMP2; PIK3CB; MAPK14; TP53; HIF1A; ESR1; MET |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.984E-07 | 2.821E-05 | CYP2C9; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.306E-06 | 2.994E-05 | DNMT1; MAOA; GAA; AKR1B1; ALOX12; PTGS2; CYP2C19; PGD; CYP3A4; PTGS1; CYP2C9; FUT7; PKM; CYP1A2; ALDH1A1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.537E-06 | 3.016E-05 | CYP2C9; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.011E-05 | 1.442E-04 | PIK3CA; MMP2; BCL2; PIK3CB; MAPK14 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.586E-05 | 1.892E-04 | PIK3CA; MMP2; BCL2; PIK3CB; PTGS2; HIF1A; MET; TP53 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 4.590E-06 | 7.206E-05 | PIK3CA; BCL2; PIK3CB; PTGS2; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.335E-06 | 2.994E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.627E-06 | 6.328E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19; PTGS2 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.531E-05 | 1.892E-04 | MMP14; PIK3CA; PIK3CB; MAPK14; PTGS2 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.078E-05 | 1.892E-04 | DNMT1; ABCB1; PIK3CA; BCL2; PTGS2; TP53; MET |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.329E-05 | 1.892E-04 | SYK; PIK3CA; BCL2; PIK3CB; MAPK14; TP53 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.152E-05 | 1.892E-04 | PIK3CA; PIK3CB; TP53; ESR1; HIF1A |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.950E-05 | 1.892E-04 | PIK3CA; PIK3CB; PTGS2; PTGS1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.531E-05 | 1.892E-04 | POLB; PKM; SYK; PIK3CA; PIK3CB; TP53 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.333E-05 | 1.892E-04 | PIK3CA; BCL2; PIK3CB; MAPK14; TP53 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.527E-05 | 1.892E-04 | PIK3CA; SYK; PIK3CB; MAPK14; PTGS1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.333E-05 | 1.892E-04 | PIK3CA; BCL2; PIK3CB; MAPK14; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.889E-05 | 2.802E-04 | PIK3CA; LMNA; BCL2; PIK3CB; TP53 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.741E-05 | 1.956E-04 | PIK3CA; PIK3CB; MAPK14; PTGS2 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.924E-05 | 1.996E-04 | PIK3CA; BCL2; PIK3CB; TP53 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 4.215E-05 | 2.545E-04 | PIK3CA; SYK; PIK3CB; MAPK14 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.746E-05 | 2.352E-04 | PIK3CA; PIK3CB; MET; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.526E-05 | 2.307E-04 | CYP2C9; CYP1A2; ALDH1A1; CYP3A4 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 4.997E-05 | 2.802E-04 | PIK3CA; PIK3CB; TP53; MET |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 5.279E-05 | 2.858E-04 | PIK3CA; PIK3CB; MAPK14; ESR1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.209E-04 | 6.325E-04 | PIK3CA; BCL2; PIK3CB; TP53 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.754E-04 | 8.886E-04 | PIK3CA; ALOX12; PIK3CB; MAPK14 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.825E-04 | 8.951E-04 | PIK3CA; MMP2; PIK3CB; ESR1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.103E-04 | 1.714E-03 | SYK; PIK3CA; BCL2; PIK3CB; TP53; MET |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.125E-04 | 1.011E-03 | PIK3CA; BCL2; PIK3CB; HIF1A |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.573E-04 | 1.558E-03 | PIK3CA; BCL2; PIK3CB; MAPK14 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 3.573E-04 | 1.558E-03 | PIK3CA; MMP2; PIK3CB; MAPK14 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 5.462E-04 | 2.093E-03 | PIK3CA; SYK; PIK3CB; MAPK14 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 7.972E-04 | 2.825E-03 | PIK3CA; BCL2; PIK3CB; TP53 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 8.326E-04 | 2.825E-03 | POLB; TERT; PIK3CA; PIK3CB; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.620E-04 | 2.101E-03 | PIK3CA; PIK3CB; MAPK14; TP53 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 8.388E-04 | 2.825E-03 | PIK3CA; BCL2; PIK3CB; MAPK14 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 3.466E-04 | 1.558E-03 | PKM; PIK3CA; PIK3CB |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 5.466E-04 | 2.093E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 4.393E-04 | 1.768E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 6.693E-04 | 2.444E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.627E-03 | 6.990E-03 | PIK3CA; BCL2; PIK3CB; MET |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 3.073E-03 | 7.781E-03 | PIK3CA; PIK3CB; MAPK14; MET |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 8.458E-04 | 2.825E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.185E-03 | 3.578E-03 | PIK3CA; SYK; PIK3CB |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.232E-03 | 6.372E-03 | MMP14; MMP2; MAPK14 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 8.843E-04 | 2.892E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.375E-03 | 6.542E-03 | PIK3CA; SYK; PIK3CB |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.185E-03 | 3.578E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.756E-03 | 7.211E-03 | PIK3CA; PIK3CB; MAPK14 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 4.148E-04 | 1.714E-03 | BCL2; MAPK14; TP53 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 2.448E-03 | 6.628E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.001E-03 | 7.725E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.435E-03 | 4.251E-03 | PIK3CA; PIK3CB; MET |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.375E-03 | 6.542E-03 | SYK; BCL2; PTGS2 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.093E-03 | 3.503E-03 | ABCB1; CA2; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.185E-03 | 3.578E-03 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.916E-03 | 9.175E-03 | PIK3CA; BCL2; PIK3CB |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 3.260E-03 | 7.966E-03 | PIK3CA; PIK3CB; MAPK14 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.440E-03 | 8.183E-03 | PIK3CA; PIK3CB; MAPK14 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.260E-03 | 7.966E-03 | PIK3CA; PIK3CB; MAPK14 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 6.475E-03 | 1.432E-02 | PIK3CA; PIK3CB; MAPK14 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 6.746E-03 | 1.471E-02 | PIK3CA; SYK; PIK3CB |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 6.885E-03 | 1.481E-02 | PIK3CA; PIK3CB; TP53 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.036E-02 | 2.086E-02 | PIK3CA; PIK3CB; PTGS2 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 8.053E-03 | 1.664E-02 | PIK3CA; SYK; PIK3CB |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 7.751E-03 | 1.622E-02 | PIK3CA; PIK3CB; MAPK14 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.036E-02 | 2.086E-02 | PIK3CA; BCL2; PIK3CB |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.364E-02 | 2.611E-02 | PIK3CA; PIK3CB; MAPK14 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.223E-02 | 2.370E-02 | BACE1; APP; MAPT |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.427E-02 | 2.654E-02 | SYK; BCL2; MAPK14 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.470E-02 | 2.684E-02 | HPGD; TP53; MET |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 2.695E-02 | 4.650E-02 | PIK3CA; PIK3CB; MET |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.558E-02 | 4.461E-02 | PIK3CA; PIK3CB |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.843E-02 | 3.251E-02 | MAPK14; PTGS2 |
| hsa00562 | Inositol phosphate metabolism_Homo sapiens_hsa00562 | 1.749E-02 | 3.120E-02 | PIK3CA; PIK3CB |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.437E-02 | 2.654E-02 | PIK3CA; PIK3CB |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.612E-02 | 2.909E-02 | MAPK14; MET |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.152E-02 | 2.289E-02 | PIK3CA; PIK3CB |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.191E-02 | 2.337E-02 | CYP1A2; CYP3A4 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 7.303E-03 | 1.550E-02 | PIK3CA; PIK3CB |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 6.094E-03 | 1.367E-02 | MMP2; TP53 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 5.527E-03 | 1.276E-02 | PIK3CA; PIK3CB |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 5.807E-03 | 1.321E-02 | MAOA; CYP1A2 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.298E-03 | 7.966E-03 | GAA; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.943E-03 | 5.649E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.417E-02 | 2.654E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; SYK |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1; SYK; HIF1A; TP53; PIK3CA; PIK3CB; MET; CA9; PKM; MMP2; MMP14 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; AKR1B1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; PTGS1 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; SYK; SYK |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; MAPK14 |
| C00-D49: Neoplasms | Cancer | C00-C96 | BCL2; BCL2; ABCB1; PTGS2; SYK; HIF1A; TP53; PIK3CA; PIK3CB; CA1; MET; MAPK14; CA9; ESR1; ESR1; DNMT1; MMP2; NQO2; APP |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2 |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MAPK14 |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | BCL2; MAPK14 |
| C00-D49: Neoplasms | Prostate cancer | C61 | BCL2; ESR1; TERT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2; MAPK14; PTGS1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; MAOA; MAPT; APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1; PTGS1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; PTGS2; PTGS2; PTGS2; SYK; MAPK14; AKR1B1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | SLC6A2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1; PTGS2; MET; DNMT1 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; PTGS2; MAOA; PTGS1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; DNMT1; DNMT1; TERT |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | SLC6A2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | SLC6A2; SLC6A2; SLC6A2; SLC6A2; MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | DNMT1; DNMT1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | BCL2; TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| NA: NA | Inflammatory diseases | NA | MAPK14 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; SYK; MAPK14; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1; PKM; SLC6A2; PTGS1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; MMP2; PTGS1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1; TERT; MMP2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; SLC6A2; MAOA |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; PIK3CA; DNMT1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | BCL2; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; MMP2; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Breast cancer | C50 | BCL2; CA9; ESR1; ESR1; TERT; NQO2 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2; HIF1A; CA9 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | SLC6A2; MAOA; MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; MAPK14; PTGS1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Melanoma | C43 | TERT |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK; PIK3CB |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; TERT; MMP2 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |